Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy.
作者信息
Lu Chunwan, Liu Kebin
机构信息
Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA, USA.
Georgia Cancer Center, Augusta University, Augusta, GA, USA.
出版信息
Transl Cancer Res. 2017 May;6(Suppl 3):S652-S654. doi: 10.21037/tcr.2017.05.32.
Abstract
摘要
相似文献
1
Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy.程序性死亡受体配体1（PD-L1）表达的表观遗传调控与胰腺癌对检查点免疫疗法的反应
Transl Cancer Res. 2017 May;6(Suppl 3):S652-S654. doi: 10.21037/tcr.2017.05.32.
2
Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy.癌症中PD-L1表达的调控及其在免疫治疗中的临床意义。
Am J Cancer Res. 2020 Jan 1;10(1):1-11. eCollection 2020.
3
HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer.组蛋白去乙酰化酶 3 通过增加胰腺癌中 PD-L1 的表达来调节癌症免疫。
Pancreatology. 2019 Mar;19(2):383-389. doi: 10.1016/j.pan.2019.01.011. Epub 2019 Jan 16.
4
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.PD-1/PD-L1 检查点阻断免疫疗法中的预测生物标志物。
Cancer Treat Rev. 2015 Dec;41(10):868-76. doi: 10.1016/j.ctrv.2015.11.001. Epub 2015 Nov 10.
5
Current studies of immunotherapy in head and neck cancer.头颈部癌免疫治疗的当前研究。
Clin Otolaryngol. 2018 Feb;43(1):13-21. doi: 10.1111/coa.12895. Epub 2017 May 29.
6
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
7
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.癌症免疫治疗中 PD-L1 调控的生化方面。
Trends Biochem Sci. 2018 Dec;43(12):1014-1032. doi: 10.1016/j.tibs.2018.09.004. Epub 2018 Oct 1.
8
Gene code : from molecular basis toward cancer immunotherapy.基因编码：从分子基础到癌症免疫治疗
Ther Adv Med Oncol. 2018 Dec 17;10:1758835918815598. doi: 10.1177/1758835918815598. eCollection 2018.
9
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.用于检查点阻断免疫疗法的潜在生物标志物及治疗策略。
Tumour Biol. 2016 Apr;37(4):4251-61. doi: 10.1007/s13277-016-4812-9. Epub 2016 Jan 16.
10
PD-1/PD-L1 and immunotherapy for pancreatic cancer.PD-1/PD-L1 与胰腺癌的免疫治疗。
Cancer Lett. 2017 Oct 28;407:57-65. doi: 10.1016/j.canlet.2017.08.006. Epub 2017 Aug 18.
引用本文的文献
1
Programmed Death-1 Ligand 1 Domain Organization, Signaling Motifs, and Interactors in Cancer Immunotherapy.癌症免疫治疗中的程序性死亡-1配体1结构域组织、信号基序及相互作用分子
Cancers (Basel). 2025 May 12;17(10):1635. doi: 10.3390/cancers17101635.
2
Verticillin A-Loaded Surgical Buttresses Prevent Local Pancreatic Cancer Recurrence in a Murine Model.载有绿胶霉素A的手术支撑物可预防小鼠模型中局部胰腺癌的复发。
Mol Pharm. 2025 Mar 3;22(3):1220-1229. doi: 10.1021/acs.molpharmaceut.4c00589. Epub 2025 Jan 27.
3
Genetics and Therapeutic Responses to Tumor-Infiltrating Lymphocyte Therapy of Pancreatic Cancer Patient-Derived Xenograft Models.胰腺癌患者来源异种移植模型的遗传学及对肿瘤浸润淋巴细胞治疗的反应
Gastro Hep Adv. 2022 Jul 15;1(6):1037-1048. doi: 10.1016/j.gastha.2022.07.006. eCollection 2022.
4
Verticillins: fungal epipolythiodioxopiperazine alkaloids with chemotherapeutic potential.青枯菌素：具有化疗潜力的真菌表二氧杂环戊烯基哌嗪类生物碱。
Nat Prod Rep. 2024 Sep 18;41(9):1327-1345. doi: 10.1039/d3np00068k.
5
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity.脂质纳米颗粒递送组成型激活的 STING mRNA 以刺激抗肿瘤免疫。
Int J Mol Sci. 2022 Nov 22;23(23):14504. doi: 10.3390/ijms232314504.
6
Rabies virus infection in mice up-regulates via epigenetic modifications.小鼠中的狂犬病病毒感染通过表观遗传修饰上调。
Virusdisease. 2020 Sep;31(3):388-394. doi: 10.1007/s13337-020-00588-w. Epub 2020 May 12.
7
The Oncogenic Potential of SUV39H2: A Comprehensive and Perspective View.SUV39H2的致癌潜力：全面且具前瞻性的观点
J Cancer. 2019 Jan 1;10(3):721-729. doi: 10.7150/jca.28254. eCollection 2019.
本文引用的文献
1
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.JAK-STAT介导的慢性炎症会损害细胞毒性T淋巴细胞的激活，从而降低抗PD-1免疫疗法在胰腺癌中的疗效。
Oncoimmunology. 2017 Feb 10;6(3):e1291106. doi: 10.1080/2162402X.2017.1291106. eCollection 2017.
2
The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.MLL1-H3K4me3轴介导的PD-L1表达与胰腺癌免疫逃逸
J Natl Cancer Inst. 2017 Jan 28;109(6). doi: 10.1093/jnci/djw283. Print 2017 Jan.
3
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells.肿瘤诱导的髓源性抑制细胞中PD-L1的表达谱及调控
Oncoimmunology. 2016 Oct 20;5(12):e1247135. doi: 10.1080/2162402X.2016.1247135. eCollection 2016.
4
Deubiquitination and Stabilization of PD-L1 by CSN5.CSN5介导的PD-L1去泛素化及稳定性维持
Cancer Cell. 2016 Dec 12;30(6):925-939. doi: 10.1016/j.ccell.2016.10.010. Epub 2016 Nov 17.
5
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.帕博利珠单抗对比多西他赛用于治疗后 PD-L1 阳性的、晚期非小细胞肺癌（KEYNOTE-010）：一项随机对照试验。
Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
6
H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance.H3K9三甲基化使Fas表达沉默，从而导致结肠癌免疫逃逸和5-氟尿嘧啶化疗耐药。
J Immunol. 2015 Aug 15;195(4):1868-82. doi: 10.4049/jimmunol.1402243. Epub 2015 Jul 1.
7
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
8
The role of CD95 and CD95 ligand in cancer.CD95和CD95配体在癌症中的作用。
Cell Death Differ. 2015 May;22(5):885-6. doi: 10.1038/cdd.2015.25.
9
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.诱导 T 细胞免疫克服对 PD-1 和 CTLA-4 阻断的完全抵抗并改善胰腺癌患者的生存。
Cancer Immunol Res. 2015 Apr;3(4):399-411. doi: 10.1158/2326-6066.CIR-14-0215. Epub 2015 Feb 12.
10
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.癌症患者对抗PD-L1抗体MPDL3280A反应的预测性相关因素。
Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.
Zotero 插件